ReNeuron jumps on stem cell study results

Shares in AIM-listed stem cell business ReNeuron Group rose on Tuesday morning after the group unveiled details of progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients.

Shares in AIM-listed stem cell business ReNeuron Group rose on Tuesday morning after the group unveiled details of progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients.

The group said that the primary aim of the study was to test the safety and tolerability of the treatment in ascending doses of the ReN001 cells in patients with moderate to severe functional neurological impairments resulting from their stroke.

The secondary aim of the study is to evaluate efficacy measures for the design of future clinical trials with ReN001, including imaging measures as well as a number of tests of sensory, motor and cognitive functions.

Interim data from the first nine patients treated in the PISCES study was being presented by the clinical team from Glasgow's Southern General Hospital at the 22nd European Stroke Conference, taking place in London this week, the group said.

It added that there was no cell-related or immunological adverse events reported in any of the patients treated and sustained reductions in neurological impairment and spasticity were observed in most patients compared with their stable pre-treatment baseline performance.

Michael Hunt, Chief Executive Officer of ReNeuron, said: "The PISCES study continues to yield encouraging results. Assuming the remaining required short-term follow up data confirm the good safety profile of the treatment, we will be able to move the ReN001 therapy confidently into Phase II clinical development, as planned, later this year."

He added: "This will represent yet another important milestone for ReNeuron, maintaining the company's pre-eminent position in the development of a neural stem cell-based treatment for disabled stroke patients."

ReNeuron's share price was up 12.24% to 2.75p at 10.45 on Tuesday morning.

MF

Recommended

Why it pays to face up to your investment mistakes
Investment strategy

Why it pays to face up to your investment mistakes

Buying stocks can be a complicated business. But selling stocks can be tricky, too – even if you sell for the right reasons. Max King explains how to …
17 Sep 2021
Share tips of the week – 17 September
Share tips

Share tips of the week – 17 September

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
17 Sep 2021
Royal Mail will deliver for investors – here's how to play it
Trading

Royal Mail will deliver for investors – here's how to play it

Royal Mail Group has found its feet in the past 18 months and looks cheap. Matthew Partridge looks at how to trade the shares.
14 Sep 2021
The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021

Most Popular

The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
Should investors be worried about stagflation?
US Economy

Should investors be worried about stagflation?

The latest US employment data has raised the ugly spectre of “stagflation” – weak growth and high inflation. John Stepek looks at what’s going on and …
6 Sep 2021